特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 会议时间： 202 5年8月12日 主办单位： 仪器信息网 支持单位： 北京普天德胜科技孵化器有限公司 会议日程： | | 08月12日 | 外泌体研究新技术新方法 | | | | --- | --- | --- | --- | --- | | 0 | 09:00--09:30 | 细胞外囊泡标准化体系建设 | 杨延莲 | 国家纳米科学中心 研究员 | | 0 | 09:30 -- 10:00 | 单分子表征技术在外泌体研究中的应用 | 孙加星 | 厦门福流生物科技有限公司 应用工程师 | | 0 | 10:00 -- 10:30 | 面向临床应用的细胞外囊泡分离富集新方法研 | 袁辉明 | 中国科学院广州生物医药与健康研究院 研 | | | | 究 | | 究员 | | O | 10:30--11:00 | 超速离心技术加速外泌体研究 | 王旭 | Eppendorf 产品经理 | | 0 | 11:00 -- 11:30 | 细胞外囊泡与颗粒的异质性解析 | 米庭 | 上海交通大学 长聘副 ...

持续报名中：2025第三届中国整形外科创新转化大赛 验证中心项目启动会 | 动物实验与创业 | 医疗器械创新（广州） | 医美行业交流（苏州） | 医美行业交流 （上海）| 化妆品原料研讨（广州） | 药用植物与美容 | 家用美容仪 ｜ 医美新材料：琼脂糖&羟基磷灰 石 | 医美光电设备交流：国产超声刀、热玛吉 ｜注射类医美投资趋势与市场机遇 ｜ 医美疤痕修复产品 与创新趋势交流会 成果路演：八大处整形医院专场推介项目大全 第二届八大处整形美容产业论坛 | 第二届整形外科创新转化大赛 | 医美投资分论坛 | 注册与申报分论坛 | 临床研究分论坛 皮肤作为人体最大的器官，在创伤、慢性病与医疗美容等多种情境中，其修复效率 始终是 临床与工程交叉研究 的重点。近年来， 外泌体与水凝胶 的结合，正在成为 促进皮肤组织再生与精准修复的关键技术路径。 外泌体 具备良好的生物活性与信号调控功能， 水凝胶 则以其高度的生物相容性与 可控递送能力，成为理想的 "智能载体" 。这两类技术的融合，正为 慢性创面、术 后修复、医美损伤干预 等应用场景带来新的材料解决方案。 本次活动，我们特别邀请在该方向深耕多年的 北京航空航天大学医 ...

Group 1 - The report highlights that the exosome industry is in its early stages of industrialization, with significant growth potential anticipated in the coming years [3][8][9] - Exosomes, which are nano-sized vesicles involved in intercellular communication, play crucial roles in tumor progression, immune regulation, and metastasis, with applications in early cancer detection and treatment guidance [3][8] - The global exosome market is projected to grow from USD 112.25 million in 2022 to approximately USD 1.5 billion by 2030, reflecting a compound annual growth rate (CAGR) of 32.75%, with around 30% of applications in oncology and 50% of revenue generated by biopharmaceutical companies [3][8] Group 2 - The report notes that there are currently at least 46 companies in China engaged in exosome research and development, focusing on areas such as separation, purification, detection, new drug development, delivery, and diagnostics [3][8] - The industrialization of exosomes is still in its nascent phase, with only a few products available in the disease diagnosis sector, while drug delivery applications remain in early development without any products on the market [9] - The report emphasizes that the lack of a clear competitive landscape presents substantial opportunities for new entrants in the exosome industry [9]

Core Viewpoint - The study reveals that exosomes derived from macrophage-derived foam cells in atherosclerotic plaques exacerbate ischemic white matter injury and vascular cognitive impairment by transmitting metabolic defects to microglia [2][5][10]. Group 1: Research Findings - Atherosclerosis (AS) is identified as an independent risk factor for vascular cognitive impairment (VCI), with unclear mechanisms [2]. - The research team discovered that exosomes in the circulation of AS patients worsen ischemic white matter injury and VCI [5]. - Foam cells produce exosomes that target microglia in the central nervous system, transmitting oxidative stress imbalance and metabolic defects through the miR-101-3p-Nrf2-Slc2a1 signaling axis [5][7]. Group 2: Potential Therapeutic Targets - The study confirms that inhibiting miR-101-3p or activating Nrf2 can counteract the effects of atherosclerotic exosomes and improve vascular cognitive impairment [6][7]. - The findings suggest a long-distance connection between peripheral macrophages and microglia, providing new insights and potential therapeutic targets for atherosclerosis-induced vascular cognitive impairment [3][10].